← All trials
NCT05212532
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 9, 2021
- Primary completion
- Feb 28, 2022
- Completion date
- Mar 30, 2022
- First posted
- Jan 28, 2022
- Last posted
- Jan 28, 2022
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- EOM PharmaceuticalsLead sponsor
- Hospital Casa de Saúde - Vera Cruz - Campinas - SP - BrazilOverall official - principal investigator
- Hospital Casa de Saúde - Vera Cruz - Campinas - SP - BrazilOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.